Impact of the COVID-19 Pandemic on Diagnosis and Multidisciplinary Treatment of NSCLC in Ontario, Canada [0.03%]
COVID-19大流行对加拿大安大略省非小细胞肺癌诊断和多学科治疗的影响
Kirstin Perdrizet,Lisa W Le,Anthea Lau et al.
Kirstin Perdrizet et al.
Introduction: The coronavirus disease 2019 pandemic disrupted cancer care delivery globally, with many jurisdictions reporting reductions in lung cancer diagnoses and delays in treatment. In Ontario, Canada, both institut...
Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report [0.03%]
托珠单抗治疗达伏拉普玛布与 tremelimumab 联合化疗后出现的类固醇冲击难治性细胞因子释放综合征一例报告
Ken Yamamoto,Katsuya Hirano,Temiko Shimada et al.
Ken Yamamoto et al.
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threa...
Role of Quality of Life in Daily Functioning, Communication with Care Teams, and Treatment Decisions in Patients with ALK+ NSCLC [0.03%]
ALK阳性NSCLC患者中的生活质量及其在日常功能、与医护团队沟通及治疗决策中的作用
Heather Law,Huamao M Lin,Eileen Curran et al.
Heather Law et al.
Introduction: This study investigated quality of life (QoL) and its role in treatment decision making among patients with anaplastic lymphoma kinase (ALK)+ NSCLC. ...
CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB-IIIA NSCLC [0.03%]
CANOPY-N：一项I至III期可切除非小细胞肺癌的新辅助治疗2期研究，单独或联合使用卡那奴单抗或派姆单抗
Jay M Lee,Jean-Louis Pujol,Jun Zhang et al.
Jay M Lee et al.
Introduction: Canakinumab is a human monoclonal anti-interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation. ...
Occult Node Detection With Lobectomy Versus Segmentectomy for Stage IA NSCLC [0.03%]
IA期非小细胞肺癌 occult 节段切除与楔形切除术的对比研究
Yota Suzuki,Rajeev Dhupar,Inderpal S Sarkaria et al.
Yota Suzuki et al.
Objective: Besides the discussion on parenchymal margin, data on the extent of lymph node (LN) dissection are scarce, especially in segmentectomy. This study aimed to investigate the extent of LN dissection and detection ...
Early Weight Gain as a Risk Factor for Increased Maximum Weight Gain Among Patients With NSCLC on Lorlatinib and Other ALK Tyrosine Kinase Inhibitors [0.03%]
洛拉替尼和其他ALK酪氨酸激酶抑制剂治疗的NSCLC患者的早期体重增加是最大体重增加的风险因素
Alexander S Watson,Alyse W Staley,Benjamin Yoder et al.
Alexander S Watson et al.
Introduction: Therapy-associated weight gain affects the quality of life and health of patients with ALK-positive NSCLC treated with tyrosine kinase inhibitors (TKIs). The severity and timing of real-world weight gain on ...
Acquisition of FGFR1 and NSD3 Amplifications During the Transformation of EGFR-Mutated Lung Adenocarcinoma into Squamous Cell Carcinoma: A Case Report [0.03%]
携带EGFR突变的肺腺癌向鳞状细胞癌转化过程中FGFR1和NSD3扩增的获得：病例报告
Naoki Fukunaga,Hideki Terai,Rui Nomura et al.
Naoki Fukunaga et al.
Histologic transformation from adenocarcinoma to SCLC is a recognized mechanism of resistance in lung cancer. However, the transformation into squamous cell carcinoma is less common, and the associated genomic alterations remain unclear. He...
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib Treatment [0.03%]
二代奥希替尼治疗期间纵向循环肿瘤DNA引导的抗性分析
J W Tijmen van der Wel,Merel Jebbink,Vincent van der Noort et al.
J W Tijmen van der Wel et al.
Introduction: In osimertinib-treated EGFR mutation (EGFRm)-positive NSCLC, resistance inevitably occurs. Early resistance mechanism (RM) detection by circulating tumor DNA (ctDNA) in plasma and consecutive targeted treatm...
Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC [0.03%]
晚期接受免疫检查点抑制剂治疗的患者2年以上延迟发生不良事件的发病率及与生存率的关系：一项关于晚期NSCLC患者的分析研究
Omar Elghawy,Adam Barsouk,Jonathan H Sussman et al.
Omar Elghawy et al.
Background: Limited data are available on late immune-related adverse events (IRAEs) in patients with metastatic NSCLC receiving immunotherapy (ICI) beyond 2 years. ...
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis [0.03%]
可切除早期非小细胞肺癌新辅助、围手术期和辅助化疗免疫治疗III期临床试验的全面回顾和详细分析
Jay M Lee,Alessandro Brunelli,Amy L Cummings et al.
Jay M Lee et al.
Phase 3 trials of neoadjuvant, perioperative, and adjuvant immune checkpoint inhibitors combined with chemotherapy (ICI-CT) in resectable early-stage NSCLC (eNSCLC) have reported that all three approaches confer an event-free or disease-fre...